Co-Diagnostics Inc (CODX)

[Opti Mist]

A clinical trial for an Emergency Use Authorization is not particularly large in terms of the number of patients. So we anticipate that, that will be concluded in relatively short term once we begin them in January of 2023. Once we compile the data and submit it to the FDA, it's up to the FDA as to how soon they respond to us. So that's kind of a - where we lose control of the timing mechanism. You also asked about our - how we view COVID in relation to our at-home and point of care.